Management and outcome of different types of ventricular tachycardia associated with hypokalemia

Figures

• 

  Figure 1. Serum potassium levels (A) and outcomes of patients with hypokalemia-related sustained monomorphic ventricular tachycardia (SMVT) vs polymorphic ventricular tachycardia/ventricular fibrillation (PMVT/VF) (B–D). B: Twenty-four–month ventricular tachycardia (VT) recurrence rate. C: Twenty-four–month survival. D: Twenty-four–month VT-free survival.

• 

  Figure 2. Ventricular tachycardia/ventricular fibrillation (VT/VF)–free survival according to hypokalemia severity and ventricular arrhythmia subtype. In the subgroup of patients with mild hypokalemia (A), there was no difference between patients with sustained monomorphic ventricular tachycardia (SMVT) and those with polymorphic VT/VF (PMVT/VF). In cases of moderate (B) and severe (C) hypokalemia, patients with PMVT/VF had significantly better VT/VF-free survival than did those with SMVT.

• 

  Figure 3. Outcomes of patients with hypokalemia-related sustained monomorphic ventricular tachycardia (SMVT) according to management strategy: ventricular tachycardia–targeted therapies (VTTTs+; potassium supplementation with additional antiarrhythmic treatment) vs no ventricular tachycardia–targeted therapies (VTTTs−; potassium supplementation without additional antiarrhythmic treatment). A: Twenty-four–month ventricular tachycardia (VT) recurrence rate. B: Twenty-four–month survival. C: Twenty-four–month VT-free survival.